The short-term (6-month) outcomes were assessed using the Liverpool score by the same pediatric neurologist
The short-term (6-month) outcomes were assessed using the Liverpool score by the same pediatric neurologist. and cognitive disorder (31.4%). Two were transferred to another hospital, 45 (91.8%) received intravenous immunoglobulins, 41 (83.7%) received methylprednisolone, and 8 (16.3%) received plasma exchange. Eight (16.3%) received rituximab for second-line treatment, six after intravenous immunoglobulin Ziyuglycoside I and methylprednisolone…